215 related articles for article (PubMed ID: 33511955)
1. Anti-VEGF Therapy in Myopic CNV.
Toto L; Di Antonio L; Costantino O; Mastropasqua R
Curr Drug Targets; 2021; 22(9):1054-1063. PubMed ID: 33511955
[TBL] [Abstract][Full Text] [Related]
2. Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization.
Sayanagi K; Uematsu S; Hara C; Wakabayashi T; Fukushima Y; Sato S; Ikuno Y; Nishida K
Graefes Arch Clin Exp Ophthalmol; 2019 Apr; 257(4):749-757. PubMed ID: 30643966
[TBL] [Abstract][Full Text] [Related]
3. The role of anti-VEGF agents in myopic choroidal neovascularization: Current standards and future outlook.
Munk MR; Rückert R; Zinkernagel M; Ebneter A; Wolf S
Expert Opin Biol Ther; 2016; 16(4):477-87. PubMed ID: 26666589
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry.
Gabrielle PH; Nguyen V; Creuzot-Garcher C; Miguel L; Alforja S; Sararols L; Casaroli-Marano RP; Zarranz-Ventura J; Gillies M; Arnold J; Barthelmes D
Acta Ophthalmol; 2022 Feb; 100(1):e288-e296. PubMed ID: 33960115
[TBL] [Abstract][Full Text] [Related]
5. Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization.
Ahn SJ; Park KH; Woo SJ
Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5794-800. PubMed ID: 26325418
[TBL] [Abstract][Full Text] [Related]
6. HOW VITREOMACULAR INTERFACE MODIFIES THE EFFICACY OF ANTI-VEGF THERAPY FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
Iacono P; Battaglia Parodi M; Iuliano L; Bandello F
Retina; 2018 Jan; 38(1):84-90. PubMed ID: 28098725
[TBL] [Abstract][Full Text] [Related]
7. Ranibizumab for myopic choroidal neovascularization.
Ng DSC; Fung NSK; Yip FLT; Lai TYY
Expert Opin Biol Ther; 2020 Dec; 20(12):1385-1393. PubMed ID: 33003962
[TBL] [Abstract][Full Text] [Related]
8. Effect of intravitreal ranibizumab injections on aqueous humour concentrations of vascular endothelial growth factor and pigment epithelium-derived factor in patients with myopic choroidal neovascularisation.
Costagliola C; Semeraro F; dell'Omo R; Romano MR; Russo A; Aceto F; Mastropasqua R; Porcellini A
Br J Ophthalmol; 2015 Jul; 99(7):1004-8. PubMed ID: 25770144
[TBL] [Abstract][Full Text] [Related]
9. FACTORS INFLUENCING VISUAL ACUITY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
Iacono P; Battaglia Parodi M; Selvi F; Parravano MC; Chiaravalloti A; Varano M; Bandello F
Retina; 2017 Oct; 37(10):1931-1941. PubMed ID: 28033235
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia.
Ohno-Matsui K; Ikuno Y; Lai TYY; Gemmy Cheung CM
Prog Retin Eye Res; 2018 Mar; 63():92-106. PubMed ID: 29111299
[TBL] [Abstract][Full Text] [Related]
11. Choroidal neovascularization secondary to pathological myopia-macular Bruch membrane defects as prognostic factor to anti-VEGF treatment.
Coelho J; Ferreira A; Abreu AC; Monteiro S; Furtado MJ; Gomes M; Lume M
Graefes Arch Clin Exp Ophthalmol; 2021 Sep; 259(9):2679-2686. PubMed ID: 33744983
[TBL] [Abstract][Full Text] [Related]
12. Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia.
Cohen SY
Retina; 2009 Sep; 29(8):1062-6. PubMed ID: 19734760
[TBL] [Abstract][Full Text] [Related]
13. Long-term effect of intravitreal injection of anti-VEGF agent for visual acuity and chorioretinal atrophy progression in myopic choroidal neovascularization.
Oishi A; Yamashiro K; Tsujikawa A; Ooto S; Tamura H; Nakata I; Miyake M; Yoshimura N
Graefes Arch Clin Exp Ophthalmol; 2013 Jan; 251(1):1-7. PubMed ID: 22527326
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for subretinal fibrosis after anti-VEGF treatment of myopic choroidal neovascularisation.
Xiao H; Zhao X; Li S; Sun L; Xin W; Wang Z; Zhang A; Zhang J; Ding X
Br J Ophthalmol; 2021 Jan; 105(1):103-108. PubMed ID: 32161005
[TBL] [Abstract][Full Text] [Related]
15. Treatment Patterns for Myopic Choroidal Neovascularization in the United States: Analysis of the IRIS Registry.
Willis J; Morse L; Vitale S; Parke DW; Rich WL; Lum F; Cantrell RA
Ophthalmology; 2017 Jul; 124(7):935-943. PubMed ID: 28372860
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor inhibitor use and treatment approach for choroidal neovascularization secondary to pathologic myopia.
Pakzad-Vaezi K; Mehta H; Mammo Z; Tufail A
Expert Opin Biol Ther; 2016 Jul; 16(7):873-81. PubMed ID: 26985834
[TBL] [Abstract][Full Text] [Related]
17. Comparison between anti-vascular endothelial growth factor therapy and photodynamic therapy for myopic choroidal neovascularization.
Matsuo M; Honda S; Matsumiya W; Kusuhara S; Tsukahara Y; Negi A
Eur J Ophthalmol; 2012; 22(2):210-5. PubMed ID: 21534251
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for myopic choroidal neovascularization-related macular atrophy after anti-VEGF treatment.
Bae KW; Kim DI; Kim BH; Oh BL; Lee EK; Yoon CK; Park UC
PLoS One; 2022; 17(9):e0273613. PubMed ID: 36137056
[TBL] [Abstract][Full Text] [Related]
19. Pharmacotherapy of Myopic Choroidal Neovascularization.
Isildak H; Schwartz SG; Flynn HW
Curr Pharm Des; 2018; 24(41):4853-4859. PubMed ID: 30674251
[TBL] [Abstract][Full Text] [Related]
20. Safety review of anti-VEGF therapy in patients with myopic choroidal neovascularization.
Ng DSC; Ho M; Iu LPL; Lai TYY
Expert Opin Drug Saf; 2022 Jan; 21(1):43-54. PubMed ID: 34228553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
